Objective: To investigate the effects of atorvastatin combined with clopidogrel on inflammatory factors, coagulation and platelet activation in patients with acute cerebral infarction. Methods: A total of 140 cases pa...Objective: To investigate the effects of atorvastatin combined with clopidogrel on inflammatory factors, coagulation and platelet activation in patients with acute cerebral infarction. Methods: A total of 140 cases patients with acute cerebral infarction who were confirmed by clinical and imaging diagnoses were randomly divided into treatment group (70 cases) and control group (70 cases). Both groups were treated routinely before treatment. The observation group was treated with clopidogrel and atorvastatin, while the control group was treated with aspirin and atorvastatin. The changes of inflammatory factors, coagulation function and platelet activation index before and after treatment were compared between the two groups. Result: Before treatment, the levels of serum soluble intercellular adhesion molecule-1 (sICAM-1), transforming growth factor-β (TGF-β), coagulation parameters prothrombin time(PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), coagulation index of platelets platelet -membrane glycoprotein (CD62p), lysosomal granular membrane glycoprotein (CD63), platelet-monocyte aggregates (PMA), coagulation parameters were not statistically significant. After treatment, the levels of sICAM-1, CD62p, CD63, PMA and FIB in both groups decreased and the levels of TGF-β, PT and APTT increased. The levels of sICAM-1, FIB, CD62p, CD63 and PMA in the observation group were (370.32±37.13) ng/mL, (1.97±0.21) g/L, (1.38±0.14)%, (0.22±0.02)%, and (18.47+1.85)% respectively, which were lower than those in the control group ((410.47±42.32) ng/mL, (2.58±0.26) s, (2.67±0.27)%, (0.35±0.03)% and (22.87±2.91)%)While the levels of TGF-β, PT and APPT were (231.53±23.52) ng/mL, (15.42±1.53) s, (37.31±3.54) s were higher than the control group ((218.56±22.17) ng/mL, (12.32±1.27) s and (29.89±3.01)s)And the differences were significant. Conclusion: Atorvastatin combined with clopidogrel treatment can effectively relieve the inflammatory response, reduce the release of inflammatory cytokines, improve blood coagulation and inhibit platelet aggregation in patients with acute cerebral infarction. So it deserves further clinical promotion.展开更多
文摘Objective: To investigate the effects of atorvastatin combined with clopidogrel on inflammatory factors, coagulation and platelet activation in patients with acute cerebral infarction. Methods: A total of 140 cases patients with acute cerebral infarction who were confirmed by clinical and imaging diagnoses were randomly divided into treatment group (70 cases) and control group (70 cases). Both groups were treated routinely before treatment. The observation group was treated with clopidogrel and atorvastatin, while the control group was treated with aspirin and atorvastatin. The changes of inflammatory factors, coagulation function and platelet activation index before and after treatment were compared between the two groups. Result: Before treatment, the levels of serum soluble intercellular adhesion molecule-1 (sICAM-1), transforming growth factor-β (TGF-β), coagulation parameters prothrombin time(PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), coagulation index of platelets platelet -membrane glycoprotein (CD62p), lysosomal granular membrane glycoprotein (CD63), platelet-monocyte aggregates (PMA), coagulation parameters were not statistically significant. After treatment, the levels of sICAM-1, CD62p, CD63, PMA and FIB in both groups decreased and the levels of TGF-β, PT and APTT increased. The levels of sICAM-1, FIB, CD62p, CD63 and PMA in the observation group were (370.32±37.13) ng/mL, (1.97±0.21) g/L, (1.38±0.14)%, (0.22±0.02)%, and (18.47+1.85)% respectively, which were lower than those in the control group ((410.47±42.32) ng/mL, (2.58±0.26) s, (2.67±0.27)%, (0.35±0.03)% and (22.87±2.91)%)While the levels of TGF-β, PT and APPT were (231.53±23.52) ng/mL, (15.42±1.53) s, (37.31±3.54) s were higher than the control group ((218.56±22.17) ng/mL, (12.32±1.27) s and (29.89±3.01)s)And the differences were significant. Conclusion: Atorvastatin combined with clopidogrel treatment can effectively relieve the inflammatory response, reduce the release of inflammatory cytokines, improve blood coagulation and inhibit platelet aggregation in patients with acute cerebral infarction. So it deserves further clinical promotion.
文摘目的:系统评价依达拉奉联合氯吡格雷对比单用氯吡格雷治疗急性脑梗死的疗效和安全性,为临床提供循证参考。方法:计算机检索Pub Med、Medline(Ovid)、中国期刊全文数据库、中文科技期刊数据库、万方数据库,收集依达拉奉联合氯吡格雷(试验组)对比单用氯吡格雷(对照组)治疗急性脑梗死的随机对照试验(RCT),对纳入研究进行质量评价和资料提取后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入18项RCT,合计1 611例患者。Meta分析结果显示,试验组患者总有效率[OR=4.07,95%CI(3.01,5.49),P<0.001]、基本痊愈率[OR=2.09,95%CI(1.68,2.59),P<0.001]、日常生活能力评分[MD=13.42,95%CI(11.62,15.23),P<0.001]均显著高于对照组,神经功能缺损评分显著低于对照组[MD=-6.20,95%CI(-8.14,-4.26),P<0.001],差异均有统计学意义。两组患者治疗后期复发率[OR=0.52,95%CI(0.24,1.13),P=0.10]和不良反应发生率比较,差异均无统计学意义。结论:依达拉奉联合氯吡格雷治疗急性脑梗死的疗效显著优于单用氯吡格雷,可改善患者的神经功能缺损状态,提高日常生活能力,在安全性方面两者相当。
